Justine

I started injecting amphetamines at sixteen. They were like anti-depressants. Drugs simplify life in some ways. They gave me something to think about, to drive for, and most importantly, they muted the suffocating depression that was a legacy of my childhood.

I was diagnosed with hepatitis C in 1992, yet the diagnosis did not impact me. In 1998, I had my first flare up of hepatitis C and I felt unusually fatigued. It was the first time I realized that hepatitis C could potentially cause me serious ill health. It gave me a hell of a fright.

We all handle our health differently. Some people prefer to know as little as possible. I wanted to know what I could do to manage this disease. I enrolled in a course which introduced ideas of diet, meditation and self-management. My ALTs settled and my specialist started talking about treatment.

I went into treatment for the first time in 2000. After 10 days, my specialist instructed me to come off treatment due to what he believed to be a reaction to Interferon, but I believe I had a severe panic attack brought on by a lack of support.

After my son was born, I had another severe flare that lasted 18 months. Before my son’s birth I didn’t think about hep C much. I could sometimes go months without giving it much thought. After the birth and the subsequent flare-up, I think about it every day. I wish I could go back to just forgetting it was there. But I can’t.

Once the flare-up settled, I found a new specialist who encouraged me to undergo re-treatment. He was an amazing source of support. He also referred me to a psychiatrist for anti-depressants to stem any possible panic attacks this time around.
I started treatment, but didn’t tell many people. Over the years I have only told my husband and very close friends because I don’t want to be judged by my behaviour 28 years ago.

However, during treatment I found an online support group called Hep C Australasia. The site brought together an amazing community of people with hepatitis and gave us a forum to discuss treatment, discrimination, fears, successes, gardens, kids, dogs and anything else you can think of. These people shared my treatment journey with me.

I had to finish treatment 8 weeks early at 40 weeks as I got Tinnitus. I relapsed.

People have asked me if I would do treatment again. I would in the blink of an eye. Treatment is a relatively short time in your life. It is absolutely worth the effort if there is a chance of clearing. But could I go through a relapse again? That’s a different story. The hardest thing about the relapse was the loss of hope. I’m not sure I could take another blow like that.

Like all relapsers and non-responders, my sight is on the new treatment regimes with the protease inhibitors and polymerease. I would say now that I am cautiously interested in treatment rather than naively optimistic.

It’s easy to be simplistic and say if I didn’t have my hep C that my life would be perfect although I am sure that’s not the case. How do I feel about it? Hepatitis C is like a dysfunctional family member that you have to make peace with when you would rather run screaming from the hills. I hate hepatitis but it is a part of me – for better or worse.

Share your story now

For people living with a hepatitis condition, it really helps to know they’re not alone. That’s why we’re inviting people to share their stories.

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close